Salarius regains Nasdaq bid price compliance; merger with Decoy ongoing

Decoy Therapeutics Inc.

Regained compliance with Nasdaq's minimum bid price requirement on Sept. 4, 2025.
Subject to one-year Mandatory Panel Monitor; delisting risk if bid price falls below $1.00 again.
Must also comply with Nasdaq equity standard by Oct. 20, 2025; currently noncompliant.
Planned merger with Decoy Therapeutics to combine into Decoy Therapeutics, led by Decoy's co-founders.
Decoy aims to file IND for pan-coronavirus antiviral within 12 months and advance other pipeline programs.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.